TL;DR
Get oils, diffusers and self-care delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The CDC’s updated 2026 Antimicrobial Resistance Threats Report lists 19 pathogens and estimates they collectively cause 9.7 million U.S. infections and 50,800 deaths each year. Four drug-resistant pathogens are classified as urgent threats; the report also adds potential threats to a watch list and downgrades C. difficile from urgent to serious.
The CDC’s updated 2026 antimicrobial resistance report identifies 19 pathogens of public health concern and estimates that they collectively cause 9.7 million infections and 50,800 deaths annually in the United States. Four drug-resistant pathogens are placed in the agency’s top “urgent threat” tier, a designation intended to guide attention to infections that require aggressive action.
The urgent-threat list includes Candida auris (also called Candidozyma auris), carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae. The report describes these organisms as serious public health threats, although the risks and affected populations differ. C. auris can cause severe infections, particularly among people who are already medically ill; resistant Acinetobacter and Enterobacterales can be difficult to treat, especially in health care settings and among patients with devices such as ventilators or catheters.
CDC figures cited in the report show that reported U.S. C. auris cases rose from 48 in 2016 to 4,523 in 2023. In 2023, carbapenem-resistant Acinetobacter was associated with an estimated 9,497 hospitalizations and 817 deaths, while carbapenem-resistant Enterobacterales was associated with 14,878 hospitalizations and 1,252 deaths. These figures refer to those specific pathogens and year; they are not the annual totals for all 19 organisms.
Drug-resistant gonorrhea is also on the urgent list. The report estimates 787,000 U.S. infections in 2023 caused by drug-resistant N. gonorrhoeae and says 55.4% of gonorrhea cases that year were resistant to at least one of six antibiotics or showed elevated minimum inhibitory concentrations. The CDC also moved drug-resistant N. meningitidis into the serious-threat category and added drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria to its watch list.
Where Resistance Threatens Care
The report’s figures indicate that antimicrobial resistance affects far more than the choice of a prescription. Infections that resist available drugs can limit treatment options and place added pressure on hospitals, patients and public health systems. For people needing intensive care or procedures, an infection that is difficult to treat can complicate other medical care.
Wendy Armstrong, president of the Infectious Diseases Society of America, said resistant infections can prolong hospital stays and increase health care costs. She also warned they can make it harder for clinicians to safely provide treatments such as chemotherapy, organ transplants and joint replacements. Those are comments from the medical society’s president, not a separate estimate of the report’s economic impact.
The CDC’s categories also help distinguish established high-priority threats from organisms for which the disease burden is less certain. The watch list signals that some pathogens merit monitoring, but does not mean their current toll is equivalent to that of the urgent-threat organisms.
Products Worth Considering
Oral-B iO Series 7 Rechargeable Electric Toothbrush with 2 Brush Heads and Charging Travel Case
Oura Ring 5 Smart Ring, Gold, Size 8
Therabody JetBoots Prime Wireless Compression Boots – Short (under 29 inseam)
As an affiliate, we earn on qualifying purchases.
How the CDC Revised Its Threat List
The CDC’s 2026 report groups pathogens by threat level, including urgent, serious and concerning categories, and separately identifies organisms on a watch list. The update includes 19 pathogens across its threat categories, plus six potential threats on the watch list, according to the source report. The aggregate estimate of 9.7 million infections and 50,800 deaths applies to the pathogens covered collectively; the available source does not provide a year-by-year breakdown for that combined total.
One change is a downgrade for Clostridioides difficile, which moved from urgent to serious. The report attributes the change in part to infection-prevention measures and a decline in cases since 2011. The CDC’s update also notes newly tracked organisms and shifts in classification, reflecting changes in the agency’s assessment rather than a claim that resistance has been eliminated.
For gonorrhea, the source report says the FDA approved gepotidacin, sold as Blujepa, and zoliflodacin, sold as Nuzolvence, the previous year. It describes these as the first new antibiotics for gonorrhea in decades. The development adds treatment options, but does not remove the CDC’s concern about resistance.
“These numbers are alarming by any measure, but they are particularly sobering when infectious diseases physicians connect real patients with these statistics in their everyday experience.”
— Wendy Armstrong, president of the Infectious Diseases Society of America
Limits of the Annual Estimates
The report’s 9.7 million infections and 50,800 deaths are estimates for the listed pathogens collectively. The supplied report summary does not specify the exact measurement period behind that annual total or explain the methods used to calculate it. Readers should not interpret it as a count of deaths in a single year unless the CDC’s underlying report confirms that framing.
The source summary also does not provide individual annual death estimates for every pathogen or detail how much each organism contributed to the combined toll. The watch-list organisms are described as potential threats with uncertain disease burdens, so their inclusion is not evidence that their current impact is fully measured. The report’s classifications and figures are agency assessments; further detail would require the underlying CDC report.
Federal Action and Ongoing Surveillance
The CDC’s updated list gives health officials and clinicians a current framework for monitoring antimicrobial resistance, while hospitals and public health agencies continue infection prevention and surveillance. The source report does not identify a specific new CDC program or deadline tied to the release.
Armstrong urged Congress to pass the PASTEUR Act, which would establish a federal program to support development of antimicrobial drugs for threatening pathogens and infections. According to the report, versions of the bill remain stalled in congressional committees. Whether lawmakers advance the legislation, and what funding or drug-development outcomes would follow, remain unresolved.
Key Questions
What does the CDC estimate about these pathogens?
The CDC report estimates that the 19 pathogens in its threat categories collectively cause 9.7 million infections and 50,800 deaths annually in the United States. The source summary does not specify the exact period or methods behind the combined annual estimate.
Which pathogens are in the urgent-threat tier?
The four listed are Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae.
Why did C. difficile move to a lower category?
The report moved C. difficile from urgent to serious, citing successful infection-prevention measures as one factor and noting that case numbers have fallen since 2011. The change is a lower threat classification, not a claim that the infection no longer poses a risk.
What is the CDC watch list?
It tracks potential threats whose disease burden may be uncertain. The update added drug-resistant dermatophytes, drug-resistant H. influenzae and nontuberculous mycobacteria, among other organisms, according to the source summary.
What happens to the PASTEUR Act?
The legislation would create a federal program to support development of antimicrobial drugs for priority threats. The source report says versions of the bill remain stalled in congressional committees; it does not provide a date for further action.
Source: medpagetoday.com
